ITGBL1 and ovarian cancer: Cortez et al. [56] also indicated that ITGBL1 overexpression affected cellular adhesion, migration, and invasiveness, and ITGBL1‐overexpressing cells were significantly more resistant to cisplatin and paclitaxel in ovarian cancer.